The cleanest reason to take tongkat ali is the stress-and-mood case: in moderately-stressed adults, four weeks of a morning capsule eased tension, anger and that foggy-confused feeling on a standard mood scale. In older men whose testosterone has slipped, the same dose nudges it back toward normal over one to three months — most notice better drive and less afternoon flatness. None of this is dramatic, closer to a gentle restoration than to replacement-grade hormones, and the signal disappears in already-healthy young men. Cost is modest, effort is one capsule daily, and the real catch is picking a brand that actually third-party-tests its bottles for heavy metals.
The active compounds are a class called quassinoids, with one named eurycomanone doing most of the work. The picture from cell studies and small human trials goes like this: the compound nudges the testes to make a bit more testosterone, partly by quietening the brain's "we have enough hormone already" feedback signal, and partly by blocking the enzyme that would otherwise convert testosterone into oestrogen Low et al. 2013. Neither move pushes a healthy body above its natural ceiling. What they do is restore some of what age and chronic stress have shaved off — about a third more saliva testosterone in a stressed but otherwise normal man, not a doubling Talbott et al. 2013. That is why "restorer" is a better label than "booster": there is a baseline to climb back to, or there isn't.
What it actually does — and what it doesn't
The cleanest mood-and-stress signal comes from a 2013 trial in 63 moderately-stressed adults given 200 mg a day of a standardised root extract for four weeks. Saliva cortisol fell about 16%, saliva testosterone rose roughly a third, and on a standard mood questionnaire tension dropped 11%, anger 12%, and the foggy-confused feeling 15% Talbott et al. 2013. A longer 24-week study pairing tongkat ali with a multivitamin saw 23% improvements in emotional wellbeing and 25% in the mental-health portion of a general health survey George et al. 2018.
The testosterone story is consistent but selective. In ageing men with low or low-normal testosterone, 200 mg of a standardised extract for four to twelve weeks moves levels back into the normal range in most users and eases the symptom checklist clinicians use to track androgen deficiency — low drive, irritability, vague tiredness Chinnappan et al. 2021 Tambi et al. 2012. Active seniors of both sexes — including a small cohort of women aged 57 to 72 — see the same hormone lift along with a measurable bump in grip strength after five weeks at 400 mg a day Henkel et al. 2014. That grip-strength signal is the only direct cosmetic-shaped finding in the literature; nothing here changes your skin, and any long-run effect on how you look runs through hormone normalisation, not anything topical.
The energy lift tracks the testosterone story closely — in older men on 200 mg a day, scores on a standard fatigue scale drop noticeably from week two onward Chinnappan et al. 2021. Cognitive effects are mostly downstream of the same cortisol-and-mood normalisation; no trial has shown a direct improvement on a cognitive test in healthy people. Sleep is the dimension with the thinnest case: no measurable change in sleep quality showed up in the closest-to-clean independent trial, and a late dose can leave some people wired at bedtime instead.
For erectile function the picture is thinner still — across pooled trials, men with severe baseline erectile difficulty improved meaningfully; men with only mild difficulty did not Kotirum et al. 2015. The counterweight matters: a 2024 trial in 33 well-trained adults, averaging fourteen years of training experience and given 400 mg a day for four weeks, found no effect on body composition, mood, sleep, grip strength, cortisol, or free testosterone Antonio et al. 2024. The two pictures together are the rule. This is a substance that closes a gap. No gap, no effect.
How to take it
Take one 200 mg capsule with breakfast and give it eight to twelve weeks before deciding it works or doesn't. Subjective energy and mood often shift in the first fortnight; the hormone numbers take a month or longer to move, and you need a blood test to actually see them Chinnappan et al. 2021.
The brand matters more than the dose
Tongkat ali is one of the supplement categories where the bottle on the shelf can be very different from what the trials tested. A Malaysian survey of 100 commercial preparations found roughly one in four exceeded the country's mercury limit, with some products at five times the allowed level Ang and Lee 2006. The U.S. Department of Defense has separately flagged that some products were adulterated with sildenafil, the prescription drug behind Viagra — which gives a fake libido lift that vanishes the day the bottle runs out OPSS 2023. The fix is straightforward but non-negotiable: buy from a brand that publishes a third-party certificate of analysis covering lead, mercury, arsenic, cadmium, and a screen for erectile-dysfunction drug adulterants. Expect to pay $20 to $50 a month; the well-tested options sit toward the lower end of that range.
Who shouldn't take it
The clear no-go list is pregnancy and breastfeeding — there is no human safety data and the substance moves hormones, which is exactly the wrong combination for either. Beyond that, the cautions are softer but real.
What it isn't
It is not a steroid, a SARM, or a libido pill. Healthy men under forty looking for a performance edge will mostly waste their money — the clean independent trial in trained adults showed no effect on hormones, mood, sleep, or anything else measured Antonio et al. 2024. "Natural" is not a synonym for clean either: the contamination problem is not a fringe worry, it is the main reason the supplement is regularly flagged by safety regulators Ang and Lee 2006. And the libido effect, when it lands, mostly lives in men who had a real complaint to begin with Kotirum et al. 2015. The expensive shortcut for an already-healthy 28-year-old is not this; it is better sleep and less stress, which are free.
Adjacent reading
Sperm quality and fertility, where the mechanism story is strong but the published human trials are still thin. Use in perimenopausal and postmenopausal women, where the first dedicated randomised trials are landing now. Combinations with other adaptogenic herbs (ashwagandha, maca) sold as "men's blends" — head-to-head evidence does not exist. And the broader question of whether daily low-grade chronic stress is what's actually pulling your testosterone down: addressing that directly tends to do more work than any pill.
- — Boron is the other low-key supplement people try to nudge testosterone. Both are gentle restorers, not boosters.
- — Tongkat ali only modestly restores already-low testosterone — proper testing tells you whether you need it or something stronger.
- — Tongkat ali sourcing is the real risk; a third-party-tested bottle keeps heavy metals and hidden drugs out.
- — Like ashwagandha, tongkat ali is sold as a stress-and-hormone adaptogen — modest, real in stressed people, oversold in healthy ones.
Substance + claimed effects
Tongkat ali is a daily oral supplement made from the root of Eurycoma longifolia Jack (Simaroubaceae), a Southeast Asian shrub traditionally used in Malaysia, Indonesia and Vietnam as an aphrodisiac, anti-fatigue tonic and treatment for "male weakness." The marketed claims this entry must adjudicate are: (1) raises serum total and free testosterone, particularly in older or hypogonadal men; (2) lowers cortisol and blunts the cortisol:testosterone ratio under chronic stress; (3) improves libido and erectile function; (4) lifts mood and reduces tension/anxiety subscale scores on validated questionnaires; (5) improves sleep quality and energy; (6) improves muscle force and body composition; (7) safe at typical doses (~200–400 mg/day of a standardised water extract). The dominant active class is quassinoids, with eurycomanone the marker compound; most clinical trials use a standardised hot-water root extract (commonly the proprietary Physta®/LJ100, standardised to 0.8–1.5% eurycomanone) Chinnappan et al. 2021.
Evidence by addressing question
Mechanism
Three converging pathways carry the testosterone signal. Central HPG-axis disinhibition: eurycomanone appears to dampen oestrogen-mediated negative feedback at the hypothalamus, raising GnRH and downstream LH/FSH and so increasing the LH drive on Leydig cells Low et al. 2013. Leydig-cell aromatase inhibition: the most rigorous in vitro work shows eurycomanone bound to aromatase in molecular-docking studies with orientations and binding energies similar to formestane, and increased testosterone production dose-dependently at 0.1–10 µM; the same study showed phosphodiesterase inhibition at higher concentrations, which would prolong cAMP signalling downstream of LH receptor activation Low et al. 2013. SHBG reduction: peripheral sex-hormone-binding globulin appears to fall in some trials, liberating bioavailable free testosterone — though the meta-analytic signal is weak (6/9 trials reported no significant SHBG change) Leisegang et al. 2022. The cortisol arm has no characterised receptor mechanism; the most-cited account is "adaptogenic" HPA-axis modulation under chronic stress, which is a phenomenological label rather than a molecular mechanism Talbott et al. 2013.
Evidence
Testosterone — the most-studied endpoint. The Leisegang 2022 systematic review and meta-analysis pooled five RCTs (n = 232) and reported a significant increase in total testosterone with E. longifolia supplementation (SMD = 1.352, 95% CI 0.565–2.138, p = 0.001). The effect was concentrated in the hypogonadal subgroup (SMD = 1.861, p = 0.002); the healthy-eugonadal subgroup showed a non-significant trend (SMD = 0.760, p = 0.249) Leisegang et al. 2022. Doses across the included trials ranged 100–600 mg/day, durations 3 days to 6 months, with Physta® the dominant extract (7/9 trials). Tambi 2012 treated 76 men with late-onset hypogonadism for one month with 200 mg/day: the proportion meeting normal-range testosterone rose from 35.5% to 90.8%, and Ageing Males' Symptoms (AMS) scale scores normalised in 71.7% (vs 10.5% at baseline; p < 0.0001) Tambi et al. 2012. Chinnappan 2021 (n = 105 men, ages 50–70, baseline testosterone <300 ng/dL) showed 200 mg Physta®/day raised total testosterone significantly by week 4 (sustained through 12 weeks), reduced cortisol, improved AMS, reduced Fatigue Severity Scale scores from week 2, and increased handgrip strength — with no SHBG change in this trial Chinnappan et al. 2021. Henkel 2014 (n = 25 active seniors, ages 57–72, 400 mg/day x 5 weeks) showed significant increases in total testosterone, free testosterone, DHEA, and handgrip muscle force in both sexes Henkel et al. 2014.
Cortisol and mood. Talbott 2013 supplemented 63 moderately-stressed adults (32 M / 31 F) with 200 mg/day of a standardised hot-water root extract for 4 weeks. Salivary cortisol fell 16% vs placebo; salivary testosterone rose 37%; cortisol:testosterone ratio fell 36%. Profile of Mood States (POMS) subscales improved for tension (−11%), anger (−12%) and confusion (−15%); all p < 0.05 by ANOVA Talbott et al. 2013. George 2018 (Physta® + multivitamin vs placebo, n = 86, 24 weeks) showed large within-group SF-12 mental-component improvements (+24.6%, p < 0.001) and emotional-wellbeing improvements (+23%, p < 0.001) in the treatment arm, with parallel placebo improvements that complicate the between-group story; cortisol was not measured and the authors flag this as a limitation George et al. 2018.
Erectile function and libido. Kotirum 2015 pooled two RCTs (n = 139) on IIEF-5 outcomes: the overall pooled weighted mean difference was non-significant (0.91; 95% CI −1.50 to 3.33; I² = 89.5%), but a subgroup of men with lower baseline IIEF-5 showed a significant improvement of 2.15 points (95% CI 1.03–3.27) Kotirum et al. 2015. The same hypogonadal-responder pattern recurs across libido outcomes in Tambi 2012 and AMS sexual-symptom subscales in Chinnappan 2021 Tambi et al. 2012 Chinnappan et al. 2021.
The negative trial in healthy exercisers. Antonio 2024 (n = 33 exercise-trained males and females, mean age 33, ~14 years training experience, 400 mg/day x 4 weeks) found no between-group difference in body composition, POMS mood, PSQI sleep, handgrip strength, salivary free testosterone, or salivary cortisol — testosterone p = 0.4266, cortisol p = 0.8692 for the delta scores Antonio et al. 2024. This trial is the cleanest counter-example to the Talbott-style claims in already-eugonadal, well-trained, low-stress populations, and it is consistent with the Leisegang subgroup analysis: the effect lives in deficient populations, not healthy ones.
Sleep. Direct human RCT evidence is thin. A 33-subject Japanese trial (Toyama, 4 weeks, double-blind) found POMS vigour and friendliness improved in the active arm but did not show direct PSG or PSQI gains in healthy adults. Antonio 2024 showed no PSQI change. Murine work shows TA consolidates wakefulness during active phase and deepens slow-wave activity during the rest phase in wild-type mice, not in narcoleptic DTA mice, suggesting any sleep effect runs through an alerting/rebound mechanism rather than a sedative one. The honest call: sleep is an indirect benefit at most, mediated through cortisol/mood improvements in stressed populations; high doses taken late in the day can worsen sleep onset.
Protocol
The clinically-anchored dose is 200 mg/day of a standardised water-soluble root extract (Physta®, LJ100, or comparable), taken once in the morning with food. This dose is shared by Talbott 2013, Tambi 2012 and the 200 mg arm of Chinnappan 2021. The 400 mg/day dose used by Henkel 2014 and Antonio 2024 is typically split (200 mg AM + 200 mg midday), reflecting eurycomanone's short ~1-hour plasma half-life. Subjective effects on energy and stress can appear within 1–2 weeks, but the hormonal endpoints (total testosterone, SHBG) require a minimum 4–8 weeks for measurable change; in Chinnappan 2021 the testosterone signal first reached statistical significance at week 4 in the 200 mg arm Chinnappan et al. 2021. Doses up to 600 mg/day for 3 weeks were tolerated in a small dose-finding trial without abnormal liver/kidney chemistry. Cycling (e.g., 8 weeks on, 2–4 weeks off) is common in practice; no trial has formally compared continuous vs cycled dosing.
Contraindications
Pregnancy and breastfeeding are absolute exclusions on hormonal grounds (no human safety data; preclinical signal of HPG-axis modulation). Hormone-sensitive cancers (prostate, hormone-receptor-positive breast) are a strong relative exclusion given androgen and possible aromatase-related effects; clinical practice excludes these populations from trials. Men on exogenous testosterone replacement therapy or pharmaceutical aromatase inhibitors should not stack tongkat ali without monitoring — SHBG reduction and aromatase interference will shift the pharmacokinetics of prescribed dosing. The 2021 European Food Safety Authority opinion noted preclinical signal for potential DNA damage in animal models, contributing to the U.S. Department of Defense Operation Supplement Safety conclusion that long-term safety in humans is not fully established OPSS 2023. NIH's LiverTox 2024 update assigns a likelihood score of D (possible rare cause of clinically apparent liver injury), based on isolated case reports primarily in young male bodybuilders where concurrent anabolic-steroid use confounds causality — preexisting liver disease is a precaution and high doses warrant LFT monitoring LiverTox 2024. Caution with anticoagulants and antihypertensives is advised on a theoretical basis; no clinically documented interactions exist.
Misconceptions
(1) Tongkat ali is not a testosterone "booster" in eugonadal men. The meta-analytic effect lives almost entirely in the hypogonadal subgroup; healthy men with normal testosterone show a non-significant trend at best Leisegang et al. 2022, and a clean trial in trained adults found no signal on any endpoint Antonio et al. 2024. The honest framing is "restorer of suppressed testosterone" not "hormone amplifier." (2) Not a steroid, not a SARM, not a libido pill. The mechanism is endogenous — the body's own steroidogenesis is modulated upward from a suppressed baseline, with effect sizes orders of magnitude below pharmaceutical TRT or PDE5 inhibitors. (3) "Natural" does not mean clean. Heavy-metal contamination is a documented quality-control problem in this product class: a Malaysian survey of 100 commercial tongkat-ali-hitam preparations found 26% exceeded the Malaysian 0.5 ppm mercury limit (0.53–2.35 ppm range) Ang and Lee 2006. Sildenafil adulteration has also been documented in finished products OPSS 2023. (4) It is not fast-acting. Subjective energy/mood changes within 2 weeks are plausible; testosterone normalisation needs 4–12 weeks.
Audience
Strongest evidence: men with biochemical or symptomatic hypogonadism (testosterone <300 ng/dL), men over ~45 with AMS-positive symptoms, men with elevated SHBG suppressing bioavailable testosterone. Moderate-strength evidence: moderately-stressed adults of either sex (Talbott 2013 cohort). Weak / emerging evidence: women, particularly perimenopausal and postmenopausal — preliminary trials report mood and quality-of-life gains at 50–100 mg/day, but published RCT data in women remains thin. No useful evidence in: healthy, eugonadal, well-trained men under ~40 — the Antonio 2024 null result is the cleanest read here Antonio et al. 2024.
Failure-modes
The common pattern of "I tried it and nothing happened" resolves into: (a) the user was already eugonadal — no headroom to restore from; (b) the product was non-standardised root powder rather than a water-extract standardised to eurycomanone, delivering an unknown active dose; (c) duration was <4 weeks; (d) the product was contaminated or sildenafil-adulterated, producing transient libido effects that vanish on cessation. The complementary failure mode is "I tried it and felt jittery/can't sleep" — consistent with high-dose alerting effects and split-dose evening administration.
Practicalities
Cost: $20–50/month for clinically-supported standardised extracts at 200 mg/day; ~$240–600/year. The product class is unregulated by FDA as a dietary supplement; third-party certificates of analysis (heavy metals, microbiological, sildenafil adulteration) are the primary quality signal a consumer has. Look for: (i) standardised water extract (not root powder); (ii) named eurycomanone content (0.8–2%) or named commercial extract (Physta®, LJ100, TAF2); (iii) third-party lab certificate (e.g., Eurofins, SGS) covering Pb/Hg/As/Cd and PDE5-inhibitor screen. Morning dosing with food is standard; evening dosing risks sleep disruption.
History
Long traditional use across the Malay archipelago for fatigue, fever, malaria, and as an aphrodisiac. Western interest accelerated after Malaysia's Forest Research Institute (FRIM) collaborated with the U.S. NIH on Eurycoma anti-tumour and bioactive screening in the 1990s, leading to the development of standardised water-extract formulations (Physta®) and the patenting of the underlying extraction process. Today's commercial supplement category is largely downstream of those standardised extracts; the Malaysian government has actively promoted Eurycoma as a national botanical asset, which is part of the stakeholder picture.
Out-of-scope
Topics surfaced but not covered as primary endpoints: spermatogenesis and fertility outcomes (mechanism evidence present, clinical trials thin); body-recomposition and ergogenic claims in young trained men (Antonio 2024 null result); use in combination with other adaptogens (ashwagandha, maca) — commercial stacks lack head-to-head evidence; specific use in women's health (menopause symptom management) — warrants its own entry once Biotropics Malaysia trial data is published.
The credibility range
The optimist case. Tongkat ali is one of the few botanicals with a published meta-analysis showing a real, large effect on a measurable hormone — total testosterone, SMD = 1.352 across 5 RCTs — with effect concentrated in the population that actually has the deficit (hypogonadal men) Leisegang et al. 2022. The Talbott 2013 cortisol/mood signal is mechanistically coherent (lowered cortisol with raised testosterone) and the magnitude (16% cortisol drop, 37% salivary testosterone rise in stressed adults) is clinically meaningful, not just statistically significant. The aromatase-inhibition mechanism is supported by both in vitro Leydig-cell work and molecular docking Low et al. 2013. The safety record in trials is reassuring: gastrointestinal complaints and isolated itching, no liver/kidney signal in trial populations, no serious adverse events across the meta-analysed cohort. For a hypogonadal man not eligible for TRT, or not wanting it, the risk/benefit ratio is favourable when sourcing is controlled. Late-onset hypogonadism affects a non-trivial fraction of men over 50; the substance addresses a real prevalent problem.
The skeptic case. The literature is dominated by trials funded by or co-authored with the patent-holders of the proprietary extracts — Physta® in particular appears in 7/9 trials in the Leisegang systematic review, and several lead authors have commercial affiliations. Effect sizes that appear large in heterogeneous studies (I² was substantial across the Leisegang pool, and Kotirum's erectile-function meta-analysis showed I² = 89.5%) raise concern about between-study heterogeneity inflating pooled estimates. The clean independent trial in healthy adults (Antonio 2024) showed no effect on any endpoint Antonio et al. 2024. The cortisol claim rests largely on one 63-subject trial (Talbott) with no large independent replication. Mechanism is patchy: SHBG reduction was not significant in 6/9 trials of the Leisegang pool. Contamination and adulteration are real and recurring — the "effects" people feel from cheap unstandardised product may be sildenafil. EFSA's 2021 preclinical DNA-damage signal is unsettling and the LiverTox D-rating — while based on confounded case reports — is not zero.
Author's call. Tongkat ali is a real, modest, restorer-not-booster intervention with the strongest case in hypogonadal or chronically-stressed men over ~45 and a credible mood/stress signal in moderately-stressed adults of either sex. In healthy young eugonadal users it likely does nothing. The product class is contamination-prone; sourcing matters more than dose. Evidence sits at 3/5: positive meta-analytic signal, positive mechanism story, but small sample sizes, sponsor conflicts, and one clean negative trial in healthy users. Controversy 2/5: the field is not split, but methodologically aware skeptics push back on the proprietary-trial dominance and the healthy-population claims. Action: do (a daily supplement), cadence daily, but mark sourcing as the load-bearing variable.
Stakeholder + incentive map
- Commercial: Biotropics Malaysia (patent-holder of Physta®), HP Ingredients (LJ100), and dozens of downstream supplement brands. Industry-funded trials dominate the literature; this is the chief source of skeptic pushback.
- Government: Malaysian Ministry of Science, Technology and Innovation has promoted Eurycoma as a national bioeconomic asset; the Forest Research Institute Malaysia (FRIM) collaborated with U.S. NIH in the 1990s on the foundational chemistry.
- Clinical/academic: A small group of South African (Henkel, Bassett) and Malaysian (Tambi, Chan, George) reproductive-medicine researchers carry most of the human-trial output; cross-affiliation with industry is common.
- Community: Active forum communities (Reddit r/Testosterone, r/Nootropics, bodybuilding forums) discuss it as a TRT alternative or adjunct; experienced users emphasise sourcing and cycling.
- Regulatory skeptics: U.S. Department of Defense Operation Supplement Safety, EFSA 2021 novel-food assessment, NIH LiverTox 2024 — all express caution on long-term safety and contamination.
Population variability
The dominant moderator is baseline hormonal status. Hypogonadal men (total testosterone <300 ng/dL, or elevated SHBG with low free testosterone) show the largest and most reliable effects Leisegang et al. 2022. Eugonadal men show much smaller or null effects Antonio et al. 2024. Age co-segregates with this: most positive trials are in men ~40–72 with testosterone in the low-normal or below-normal range. Stress state modulates the cortisol arm — the Talbott cohort was screened for moderate stress, and in low-stress adults the cortisol drop is not detectable. Women: small pilots (Henkel 2014 included 12 women) show free-testosterone rises; perimenopausal trials are underway. Genetic/ethnic: virtually all trial cohorts are Malaysian, South African or U.S.-mixed; no specific signal of differential response by ancestry has been examined.
Knowledge gaps
(1) Independent (non-industry-funded) replication of the cortisol-reduction signal at scale. (2) Long-term (>6 month) safety data, particularly in older men on sustained daily use — LiverTox flags the absence of this. (3) Whether the SHBG-reduction signal is reliable or an artefact of select sub-trials. (4) Head-to-head comparison of standardised extracts (Physta® vs LJ100 vs TAF2 vs unstandardised root powder) on the same endpoints. (5) Mechanism of the cortisol effect at the molecular level — currently no characterised receptor or enzyme target. (6) Women's endpoints across the menopausal transition. (7) Whether the EFSA preclinical DNA-damage signal translates to any human risk at chronic supplemental doses.
Scope vs. brief. The brief named cortisol, free testosterone, libido, mood, sleep, and side-effect profile. All six are touched. Cortisol, testosterone and mood get the most weight because the evidence carries them; sleep is honestly marked as the thinnest endpoint (no PSQI signal in Antonio 2024; murine work is alerting rather than sedating). Libido is folded into the erectile-function paragraph in evidence — the Kotirum 2015 pooled signal is the same hypogonadal-responder pattern as the rest of the entry. Side-effect / contamination story is split: the product-class sourcing risk goes in practicalities; the medical no-go list goes in contraindications.
Rating difficulty: evidence at 3. A defensible 4 case exists — Leisegang 2022 meta-analysis with SMD = 1.35 across five RCTs is unusually strong for a botanical. The reasons it lands at 3 not 4: (i) 7 of 9 trials in the underlying pool used Physta®, with several lead authors carrying commercial affiliations; (ii) the only clean independent trial (Antonio 2024) was null on every endpoint; (iii) cortisol claim rests largely on one 63-subject trial; (iv) SHBG signal was not significant in 6/9 of the Leisegang pool, undercutting one of the proposed mechanisms.
Rating difficulty: mood at 3. Could be argued up to 4 on Talbott's 11–15% POMS subscale drops and George's 23–25% SF-12 mental-component gains. Held at 3 because: (a) effects vanish in unstressed populations; (b) George 2018's placebo arm also improved substantially (the between-group story is thinner than the within-group story); (c) no large independent replication.
Audience left unscoped despite evidence skew toward older men. The Talbott stress/mood trial included women, the Henkel 2014 senior pilot included 12 women, and the perimenopausal Physta® trial is unpublished but in the pipeline. Restricting to male would mislead by under-scoping; the article's prose carries the gendered weight where it matters (men 45+ is the strongest case) without locking the audience field.
Contraindications token vocabulary is too narrow for this entry. The closed token set captures pregnancy and breastfeeding but does not have tokens for hormone-sensitive cancers, current TRT users, or anabolic-steroid users. Those three exclusions are spelled out in the warning callout instead. Flag for a future schema-expansion review: a hormone-sensitive-cancer token would carry real load across this entry, finasteride, ashwagandha, and DHEA at minimum.
Separate-entry candidates surfaced while writing:
- Tongkat ali for perimenopause / menopause — warrants its own entry once Biotropics Malaysia's 150-woman Physta® trial publishes. Different dose (50–100 mg), different endpoints (vasomotor, MENQOL).
- Sperm quality / male fertility — mechanism story is strong, would intersect with a future male-fertility category cluster.
- Sildenafil-adulterated supplements as a category risk — would sit under medical or supplements, not specific to tongkat ali.
Future-link candidates: creatine, ashwagandha, magnesium, late-onset hypogonadism (as a condition entry), SHBG (as a biomarker entry), morning sunlight (cortisol angle), sleep debt (the underlying-driver framing in out-of-scope).
Decisions taken during the write: the Talbott 16% cortisol / 37% testosterone numbers stay in the dek because they are the public face of the literature and a reader benefits from seeing them up front; the larger-but-less-felt Leisegang SMD goes in the mechanism callout where it has room to be qualified by the hypogonadal-subgroup caveat. The Antonio 2024 null trial is named in three places (highlights, evidence, misconceptions) on purpose — the "no gap, no effect" framing is the most important thing a healthy young reader needs to walk away with, and a single mention would let it slide.
Tongkat Ali (Eurycoma longifolia)
One capsule in the morning with food. Single sourcing decision up front (third-party-tested extract); thereafter trivial.
$20–50/month for a clinically-supported standardised extract; ~$240–600/year. Sits squarely in the $50–$500/year band. Cheaper unstandardised root powder is widely available but is the same product class implicated in heavy-metal contamination surveys (Ang 2006).
Clear functional improvement on validated symptom scales within weeks: AMS (Tambi 2012, Chinnappan 2021), Fatigue Severity Scale from week 2 (Chinnappan 2021), SF-12 mental and vitality components (George 2018). The signal lives in hypogonadal/stressed populations and is absent in healthy eugonadal users (Antonio 2024).
Fatigue Severity Scale fell significantly from week 2 in 200 mg Physta arm (Chinnappan 2021); POMS vigour improved in Japanese trial; subjective energy and reduced afternoon fatigue are the most consistent reader-reported effects. Effect concentrated in low-testosterone or stress-suppressed populations; null in healthy trained adults (Antonio 2024).
Strongest non-hormonal signal. POMS tension −11%, anger −12%, confusion −15% at 200 mg/day x 4 weeks in moderately-stressed adults (Talbott 2013). SF-12 emotional wellbeing +23%, mental component +24.6% at 24 weeks with Physta+multivitamin (George 2018). AMS psychological subscale improved (Chinnappan 2021, Tambi 2012). Null in unstressed healthy adults (Antonio 2024).
Meta-analytic signal on total testosterone with SMD 1.352 (Leisegang 2022), positive RCTs on cortisol and mood (Talbott 2013, George 2018, Chinnappan 2021), and mechanism work in Leydig cells (Low 2013) — but small sample sizes (5 RCTs n=232 in main MA), strong proprietary-extract dominance (7/9 trials used Physta), industry funding common, and one clean negative independent trial in healthy adults (Antonio 2024). Worth trying with monitored sourcing; not Cochrane-tier.
No direct topical or short-term cosmetic effect. Modest, slow indirect contribution via testosterone restoration and lowered cortisol in deficient populations — lean-mass and skin secondary to hormone normalisation in older men (Henkel 2014 muscle-force signal). Speculative outside the hypogonadal subgroup.
POMS confusion subscale fell 15% in stressed adults (Talbott 2013); no direct cognitive-battery improvements demonstrated, and vigilant attention unchanged in trained adults (Antonio 2024). Likely a downstream effect of cortisol/mood normalisation rather than a primary nootropic action.
No direct human PSG or PSQI improvement demonstrated (Antonio 2024 null on PSQI). Murine work shows wakefulness consolidation rather than sedation. Plausible indirect benefit via cortisol reduction in stressed users; high doses or evening dosing reportedly worsen sleep onset.